mTORC2 promotes type I insulin-like growth factor receptor and insulin receptor activation through the tyrosine kinase activity of mTOR

Cell Research

Volumn 26, Issue 1, 2016, Pages 46-65

  Yin, Yancun ^a   Hua, Hui ^a   Li, Minjing ^b   Liu, Shu ^a   Kong, Qingbin ^a   Shao, Ting ^a   Wang, Jiao ^c   Luo, Yuanming ^d   Wang, Qian ^d   Luo, Ting ^a   Jiang, Yangfu ^a  

^a SICHUAN UNIVERSITY   (China)

^b BINZHOU MEDICAL UNIVERSITY   (China)

^c CHENGDU UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^d INSTITUTE OF MICROBIOLOGY   (China)

Author keywords

insulin receptor; insulin like growth factor receptor; mTOR; mTORC2; protein kinase

Indexed keywords

CARRIER PROTEIN; INSULIN RECEPTOR; MTOR PROTEIN, HUMAN; MULTIPROTEIN COMPLEX; PROTEIN TYROSINE KINASE; RAPAMYCIN; RICTOR PROTEIN, HUMAN; SOMATOMEDIN C RECEPTOR; TARGET OF RAPAMYCIN KINASE; TOR COMPLEX 2; TYROSINE;

CELL PROLIFERATION; HEK293 CELL LINE; HEP-G2 CELL LINE; HUMAN; METABOLISM; PHOSPHORYLATION; TUMOR CELL LINE;

CARRIER PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; HEK293 CELLS; HEP G2 CELLS; HUMANS; MULTIPROTEIN COMPLEXES; PHOSPHORYLATION; PROTEIN-TYROSINE KINASES; RECEPTOR, IGF TYPE 1; RECEPTOR, INSULIN; SIROLIMUS; TOR SERINE-THREONINE KINASES; TYROSINE;

EID: 84953347125     PISSN: 10010602     EISSN: 17487838     Source Type: Journal    
DOI: 10.1038/cr.2015.133     Document Type: Article

References (44)

1. Kim J, Kundu M, Viollet B, Guan KL. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat Cell Biol. 2011; 13: 132-141.
2. Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012; 149: 274-293.
3. Ben-Sahra I, Howell JJ, Asara JM, Manning BD. Stimulation of de novo pyrimidine synthesis by growth signaling through mTOR and S6K1. Science. 2013; 339: 1323-1328.
4. Robitaille AM, Christen S, Shimobayashi M, et al. Quantitative phosphoproteomics reveal mTORC1 activates de novo pyrimidine synthesis. Science. 2013; 339: 1320-1323.
5. Jacinto E, Loewith R, Schmidt A, et al. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol. 2004; 6: 1122-1128.
6. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science. 2005; 307: 1098-1101.
7. Sarbassov DD, Ali SM, Sengupta S, et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell. 2006; 22: 159-168.
8. Garcia-Martinez JM, Alessi DR. mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- And glucocorticoid-induced protein kinase 1 (SGK1). Biochem J. 2008; 416: 375-385.
9. Guertin DA, Stevens DM, Thoreen CC, et al. Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. Dev Cell. 2006; 11: 859-871.
10. Dibble CC, Asara JM, Manning BD. Characterization of Rictor phosphorylation sites reveals direct regulation of mTOR complex 2 by S6K1. Mol Cell Biol. 2009; 29: 5657-5670.
11. Julien LA, Carriere A, Moreau J, Roux PP. mTORC1-Activated S6K1 phosphorylates Rictor on threonine 1135 and regulates mTORC2 signaling. Mol Cell Biol. 2010; 30: 908-921.
12. Liu P, Gan W, Inuzuka H, et al. Sin1 phosphorylation impairs mTORC2 complex integrity and inhibits downstream Akt signalling to suppress tumorigenesis. Nat Cell Biol. 2013; 15: 1340-1350.
13. Kinkade CW, Castillo-Martin M, Puzio-Kuter A, et al. Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. J Clin Invest. 2008; 118: 3051-3064.
14. O'Reilly KE, Rojo F, She QB, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 2006; 66: 1500-1508.
15. Brown J, Jones EY, Forbes BE. Keeping IGF-II under control: lessons from the IGF-II-IGF2R crystal structure. Trends Biochem Sci. 2009; 34: 612-619.
16. Pollak M. The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer. 2012; 12: 159-169.
17. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer. 2008; 8: 915-928.
18. Hsu PP, Kang SA, Rameseder J, et al. The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science. 2011; 332: 1317-1322.
19. Yu Y, Yoon SO, Poulogiannis G, et al. Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling. Science. 2011; 332: 1322-1326.
20. Dai N, Christiansen J, Nielsen FC, Avruch J. mTOR complex 2 phosphorylates IMP1 cotranslationally to promote IGF2 production and the proliferation of mouse embryonic fibroblasts. Genes Dev. 2013; 27: 301-312.
21. Dai N, Rapley J, Angel M, Yanik MF, Blower MD, Avruch J. mTOR phosphorylates IMP2 to promote IGF2 mRNA translation by internal ribosomal entry. Genes Dev. 2011; 25: 1159-1172.
22. Cybulski N, Polak P, Auwerx J, Ruegg MA, Hall MN. mTOR complex 2 in adipose tissue negatively controls whole-body growth. Proc Natl Acad Sci USA. 2009; 106: 9902-9907.
23. Kumar A, Lawrence JC, Jr, Jung DY, et al. Fat cell-specific ablation of rictor in mice impairs insulin-regulated fat cell and whole-body glucose and lipid metabolism. Diabetes. 2010; 59: 1397-1406.
24. Kim SJ, DeStefano MA, Oh WJ, et al. mTOR complex 2 regulates proper turnover of insulin receptor substrate-1 via the ubiquitin ligase subunit Fbw8. Mol Cell. 2012; 48: 875-887.
25. Hernandez-Sanchez C, Blakesley V, Kalebic T, Helman L, LeRoith D. The role of the tyrosine kinase domain of the insulin-like growth factor-I receptor in intracellular signaling, cellular proliferation, and tumorigenesis. J Biol Chem. 1995; 270: 29176-29181.
26. Lopaczynski W, Terry C, Nissley P. Autophosphorylation of the insulin-like growth factor I receptor cytoplasmic domain. Biochem Bioph Res Commun. 2000; 279: 955-960.
27. Vilella-Bach M, Nuzzi P, Fang Y, Chen J. The FKBP12-rapamycin-binding domain is required for FKBP12-rapamycin-Associated protein kinase activity and G1 progression. J Biol Chem. 1999; 274: 4266-4272.
28. Gan X, Wang J, Su B, Wu D. Evidence for direct activation of mTORC2 kinase activity by phosphatidylinositol. 3, 4, 5-Trisphosphate. J Biol Chem. 2011; 286: 10998-11002.
29. Dhanasekaran N, Premkumar Reddy E. Signaling by dual specificity kinases. Oncogene. 1998; 17: 1447-1455.
30. Heitman J, Movva NR, Hall MN. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science. 1991; 253: 905-909.
31. Brown EJ, Albers MW, Shin TB, et al. A mammalian protein targeted by G1-Arresting rapamycin-receptor complex. Nature. 1994; 369: 756-758.
32. Hong F, Larrea MD, Doughty C, Kwiatkowski DJ, Squillace R, Slingerland JM. mTOR-raptor binds and activates SGK1 to regulate p27 phosphorylation. Mol Cell. 2008; 30: 701-711.
33. Bentzinger CF, Romanino K, Cloetta D, et al. Skeletal muscle-specific ablation of raptor, but not of rictor, causes metabolic changes and results in muscle dystrophy. Cell Metab. 2008; 8: 411-424.
34. Hresko RC, Mueckler M. mTOR. RICTOR is the Ser473 kinase for Akt/protein kinase B in 3T3-L1 adipocytes. J Biol Chem. 2005; 280: 40406-40416.
35. Feldman ME, Apsel B, Uotila A, et al. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol. 2009; 7: e38.
36. Hoeffer CA, Klann E. mTOR signaling: at the crossroads of plasticity, memory and disease. Trends Neurosci. 2010; 33: 67-75.
37. Niessen M, Jaschinski F, Item F, McNamara MP, Spinas GA, Trub T. Insulin receptor substrates 1 and 2 but not Shc can activate the insulin receptor independent of insulin and induce proliferation in CHO-IR cells. Exp Cell Res. 2007; 313: 805-815.
38. Harrington LS, Findlay GM, Gray A, et al. The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J Cell Biol. 2004; 166: 213-223.
39. Um SH, Frigerio F, Watanabe M, et al. Absence of S6K1 protects against age- And diet-induced obesity while enhancing insulin sensitivity. Nature. 2004; 431: 200-205.
40. Briaud I, Dickson LM, Lingohr MK, McCuaig JF, Lawrence JC, Rhodes CJ. Insulin receptor substrate-2 proteasomal degradation mediated by a mammalian target of rapamycin (mTOR)-induced negative feedback down-regulates protein kinase B-mediated signaling pathway in beta-cells. J Biol Chem. 2005; 280: 2282-2293.
41. Wei F, Liu Y, Bellail AC, et al. K-Ras mutation-mediated IGF-1-induced feedback ERK activation contributes to the rapalog resistance in pancreatic ductal adenocarcinomas. Cancer Lett. 2012; 322: 58-69.
42. Naing A, LoRusso P, Fu S, et al. Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors. Clin Cancer Res. 2012; 18: 2625-2631.
43. Schwartz GK, Tap WD, Qin LX, et al. Cixutumumab and temsirolimus for patients with bone and soft-Tissue sarcoma: a multicentre, open-label, phase 2 trial. Lancet Oncol. 2013; 14: 371-382.
44. Janes MR, Limon JJ, So L, et al. Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nat Med. 2010; 16: 205-213.